

Practitioner's Docket No. **MBIO99-057CP2M****PATENT****IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**In re application of: **Samantha J. Busfield et al.**Application No.: **09/503,387**Group: **1644**Filed: **February 14, 2000**Examiner: **HUYNH, PHOUNG N.**For: **GLYCOPROTEIN VI AND USES THEREOF****Commissioner for Patents
Washington, D.C. 20231****CHANGE OF ATTORNEY DOCKET NUMBER**

Dear Sir:

Please note that the Attorney Docket Number has been changed from **7853-178-999** to **MBIO99-057CP2M**. Please reference **MBIO99-057CP2M** on all future correspondence.

Respectfully submitted,

April 14, 2003

MILLENNIUM PHARMACEUTICALS, INC.

By


Paul J. Paglierani

Registration No. 52,498

75 Sidney Street

Cambridge, MA 02139

Telephone - 617-761-6865

Facsimile - 617-551-8820

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING☐ deposited with the United States Postal Service in an envelope addressed to the Commissioner for Patents, Washington, D.C. 20231.**37 C.F.R. SECTION 1.8(a)****37 C.F.R. SECTION 1.10***☐ with sufficient postage as first class mail.☐ as "Express Mail Post Office to Address"
Mailing Label No.**TRANSMISSION**☒ transmitted by facsimile to the Patent and Trademark Office.

Signature

Date: April 14, 2003Mary MacKinnon

(type or print name of person certifying)

***WARNING:** Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

(Page 1 of 1)

Burden Hour Statement: This form is estimated to take 0.03 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Practitioner's Docket No. MBIO99-057CP2M

PATENT

Certificate of Transmission under 37 CFR 1.8

FAX RECEIVED

APR 15 2003

I hereby certify that this correspondence is being facsimile transmitted to the
United States Patent and Trademark Office

GROUP 1600

on April 14, 2003.

Signature

Mary MacKinnon

Typed or printed name of person signing Certificate

OFFICIAL

Note: Each paper must have its own certificate of transmission, or this certificate must identify each submitted paper.

Submitted herewith:

Transmittal	(2 pages)
Revocation of Prior Powers of Attorney and Appointment of New Power of Attorney from Millennium Pharmaceuticals, Inc.	(2 pages)
Change of Attorney Docket Number	(1 page)

Total Pages

(6 pages)
(including this cover sheet)

TO/SB/97 (08-00)

Approved for use through 10/31/2002. OMB 0661-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Practitioner's Docket No. MBIO99-057CP2M

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Samantha J. Busfield et al.
Application No.: 09/503,387 Group: 1644
Filed: February 14, 2000 Examiner: HUYNH, PHUONG N.
For: GLYCOPROTEIN VI AND USES THEREOF

Commissioner for Patents
Washington, D.C. 20231

TRANSMITTAL

1. Transmitted herewith for this application is/are:
 - a. This Transmittal (2 pages);
 - b. Revocation of Prior Powers of Attorney and Appointment of New Power of Attorney executed by Millennium Pharmaceuticals, Inc. (2 pages);
 - c. Change of Attorney Docket Number (1 page).

STATUS

2. Applicant is other than a small entity.

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

- ☐ deposited with the United States Postal Service in an envelope addressed to the Commissioner for Patents, Washington, D.C. 20231.

37 C.F.R. SECTION 1.8(a)

37 C.F.R. SECTION 1.10*

- ☐ with sufficient postage as first class mail.

- ☐ as "Express Mail Post Office to Address"
Mailing Label No.

TRANSMISSION

- ☒ transmitted by facsimile to the Patent and Trademark Office.

Signature

Date: April 14, 2003

Mary MacKinnon

(type or print name of person certifying)

*WARNING: Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

(Page 1 of 2)

Practitioner's Docket No. MBIO99-057CP2M

FEE DEFICIENCY

3. If any additional extension and/or fee is required, charge Account No. 501668.
If any additional fee for claims is required, charge Account No. 501668.

April 14, 2003

MILLENNIUM PHARMACEUTICALS, INC.

By


Paul J. Paglierani

Registration No. 52,498

75 Sidney Street

Cambridge, MA 02139

Telephone - 617-761-6865

Facsimile - 617-551-8820